Search Results | Blood | American Society of Hematology

1-20 of 245

2 3 4 5

Sort by

Sort Order Select

Journal Articles

An ounce of which prevention is worth a…?

Joerg Halter, Jakob Passweg

Blood (2021) 137 (14): 1852–1853.

DOI: https://doi.org/10.1182/blood.2021010688

Published: 2021

Journal Articles

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

Blood (2021) 137 (14): 1970–1979.

DOI: https://doi.org/10.1182/blood.2020009050

Published: 2021

Includes: Supplemental data

Journal Articles

DARTs point the way forward in AML

Saar Gill

Blood (2021) 137 (6): 720–721.

DOI: https://doi.org/10.1182/blood.2020009020

Published: 2021

Journal Articles

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Blood (2021) 137 (6): 751–762.

DOI: https://doi.org/10.1182/blood.2020007732

Published: 2021

Includes: Supplemental data

Journal Articles

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Matthew J. Frigault, Sarah Nikiforow, Michael K. Mansour, Zhen-Huan Hu, Mary M. Horowitz, Marcie L. Riches, Peiman Hematti, Cameron J. Turtle, Mei-Jie Zhang, Miguel-Angel Perales, Marcelo C. Pasquini

Blood (2020) 136 (1): 137–139.

DOI: https://doi.org/10.1182/blood.2020006216

Published: 2020

Journal Articles

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

Ramya Ramaswami, Kathryn Lurain, Cody J. Peer, Anna Serquiña, Victoria Wang, Anaida Widell, Priscila Goncalves, Seth M. Steinberg, Vickie Marshall, Jomy George, William D. Figg, Denise Whitby, Joseph Ziegelbauer, Thomas S. Uldrick, Robert Yarchoan

Blood (2020) 135 (25): 2316–2319.

DOI: https://doi.org/10.1182/blood.2019004602

Published: 2020

Includes: Supplemental data

Journal Articles

The earlier the better: timely mitigation of CRS

Rayne H. Rouce

Blood (2019) 134 (24): 2119–2120.

DOI: https://doi.org/10.1182/blood.2019003618

Published: 2019

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

DOI: https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

Flow Cytometry-Based Pre-Transplant Minimal Residual Disease Detection Strongly Impacts on the Outcome of Haploidentical Transplantation with Αβ T Cell Depletion in Pediatric Acute Lymphoblastic Leukemia

Blood (2019) 134 (Supplement_1): 4618.

DOI: https://doi.org/10.1182/blood-2019-129792

Published: 2019

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

DOI: https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

Peter A. Riedell, MD, Chase Walling, BS, Loretta J. Nastoupil, MD MSc, Martina Pennisi, Richard T. Maziarz, MD, Joseph P. McGuirk, DO, Olalekan O. Oluwole, MBBS, MPH, Veronika Bachanova, MD PhD, Wei-Ting Hwang, PhD, Stephen J. Schuster, MD, Miguel-Angel Perales, MD, Michael R. Bishop, MD, David L. Porter, MD

Blood (2019) 134 (Supplement_1): 1599.

DOI: https://doi.org/10.1182/blood-2019-127490

Published: 2019

Journal Articles

HTLV-1 Dysregulates IL-6 and IL-10-JAK/STAT Signaling and Induces Leukemia/Lymphoma of Mature CD4+ T Cells with Regulatory T-Cell-like Signatures

Yusuke Higuchi, MD, Jun-ichirou Yasunaga, MD PhD, Yu Mitagami, PhD, Koichi Ohshima, MD PhD, Masao Matsuoka, MD PhD

Blood (2019) 134 (Supplement_1): 1516.

DOI: https://doi.org/10.1182/blood-2019-125546

Published: 2019

Journal Articles

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Caixia Li, Changfeng Zhang, PhD, Xiaochen Chen, Ying Zhang, Jia Chen, MD, Liqing Kang, Xiaoyan Lou, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5313.

DOI: https://doi.org/10.1182/blood-2019-126821

Published: 2019

Journal Articles

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Shuangshuang Yang, MD, Lijuan Chen, MD PhD, Jie Xu, MD PhD, Frank Xiao-Hu Fan, MD PhD, Sun Yan, PhD, Wen Wu, MD PhD, Yan Wang, MD, Jin Wang, MD PhD, Shiwei Jin, MD, Yuebo Zhou, Yuanfang Liu, MD PhD, Yan Zhuang, PhD, Wu Zhang, PhD, Jun-Min Li, Jian Hou, PhD MD, Jian-Yong Li, MD PhD, Zhu Chen, PhD, Jian-Qing Mi, MD PhD, Sai-Juan Chen, PhD

Blood (2019) 134 (Supplement_1): 5617.

DOI: https://doi.org/10.1182/blood-2019-131799

Published: 2019

Journal Articles

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Zunairah Shah, MBBS, Syeda Sabeeka Batool, MBBS, MD, Hafiz Muhammad Fazeel, MBBS, Mustafa Nadeem Malik, MD, Maryam Sadiq, MBBS, Syeda Fatima Hassan, MBBS, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Nisma Javed, MBBS, Aqsa Ashraf, MD, Arafat Ali Ali Farooqui, MD, Muhammad Abdullah Yousaf, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Marium Ghani, MBBS, Arshia Akbar, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5597.

DOI: https://doi.org/10.1182/blood-2019-131849

Published: 2019

Journal Articles

Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib

Tanya Siddiqi, MD, Jacob D. Soumerai, MD, Kathleen A. Dorritie, MD, Deborah M. Stephens, DO, Peter A. Riedell, MD, Jon E. Arnason, MD, Thomas J. Kipps, MD PhD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Jason A. Dubovsky, PhD, Julie Rytlewski, PhD, Lin Yang, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 503.

DOI: https://doi.org/10.1182/blood-2019-127603

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

DOI: https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Deepu Madduri, MD, Saad Z. Usmani, MD, Sundar Jagannath, Indrajeet Singh, PhD, Enrique Zudaire, PhD, Tzu-Min Yeh, Alicia J. Allred, PhD, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Jordan M Schecter, MD, Sen Zhuang, Jeffrey R. Infante, MD, Syed Rizvi, Xiaohu (Frank) Fan, MD PhD, Andrzej Jakubowiak, MD PhD, Jesus G. Berdeja, MD

Blood (2019) 134 (Supplement_1): 577.

DOI: https://doi.org/10.1182/blood-2019-121731

Published: 2019

Journal Articles

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

Jesus G. Berdeja, MD, Melissa Alsina, MD, Nina D. Shah, MD, David S. Siegel, Sundar Jagannath, MD, Deepu Madduri, MD, Jonathan L. Kaufman, MD, Nikhil C. Munshi, MD, Jacalyn Rosenblatt, MD, Jagoda K. Jasielec, MD, Yi Lin, MD PhD, Ashley Turka, Lyh Ping Lam, PharmD, RPh, Monica Massaro, MPH, Timothy B. Campbell, MD PhD, Kristen Hege, Fabio Petrocca, MD, Noopur S. Raje, MD

Blood (2019) 134 (Supplement_1): 927.

DOI: https://doi.org/10.1182/blood-2019-126660

Published: 2019

Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin

Blood (2019) 134 (Supplement_1): 930.

DOI: https://doi.org/10.1182/blood-2019-130340

Published: 2019

2 3 4 5

NARROW

An ounce of which prevention is worth a…?

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis

DARTs point the way forward in AML

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Tocilizumab not associated with increased infection risk after CAR T-cell therapy: implications for COVID-19?

Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus–associated multicentric Castleman disease

The earlier the better: timely mitigation of CRS

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Flow Cytometry-Based Pre-Transplant Minimal Residual Disease Detection Strongly Impacts on the Outcome of Haploidentical Transplantation with Αβ T Cell Depletion in Pediatric Acute Lymphoblastic Leukemia

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas

HTLV-1 Dysregulates IL-6 and IL-10-JAK/STAT Signaling and Induces Leukemia/Lymphoma of Mature CD4+ T Cells with Regulatory T-Cell-like Signatures

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Dynamic Analysis of Cytokine Profile for Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Cell Therapy

Role of B-Cell Maturation Antigen (BCMA) Targeted Immunotherapies in Relapsed and Refractory Multiple Myeloma- a Systematic Review

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)

Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only